Tenax Therapeutics (TENX) Long-Term Debt Issuances (2011 - 2024)
Tenax Therapeutics (TENX) posted quarterly Long-Term Debt Issuances of $279000.0 for Q3 2024, up 62.89% year-over-year from $171283.0 in Q4 2023, and up 108.21% on a QoQ basis from $134000.0 in Q2 2024.
Tenax Therapeutics (TENX) Long-Term Debt Issuances (2011 - 2024) Analysis & Trends
Tenax Therapeutics has reported Long-Term Debt Issuances for 9 years, with the latest figure at $279000.0 in Q3 2024.
- Long-Term Debt Issuances for Q3 2024 came in at $279000.0, up 62.89% year-over-year; the trailing twelve-month figure through Jun 2025 was $279000.0 (down 50.83% YoY), and the FY2024 annual result was $501000.0, down 19.71% from the prior year.
- Long-Term Debt Issuances rose to $279000.0 in Q3 2024, from $134000.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $364546.0 in Q1 2022 and troughed at -$364546.0 in Q4 2022.
- A 3-year average of $125000.0 and a median of $168157.0 in 2023 frame the typical range for Long-Term Debt Issuances.
- The largest YoY upside for Long-Term Debt Issuances was 147.78% in 2023 against a maximum downside of 69.72% in 2023.
- A 3-year view of Long-Term Debt Issuances shows it stood at -$364546.0 in 2022, then soared by 147.78% to $174164.0 in 2023, then surged by 60.19% to $279000.0 in 2024.
- Per Business Quant data, the three most recent Long-Term Debt Issuances figures were $279000.0 in Q3 2024, $134000.0 in Q2 2024, and $88000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 279,000.00 |
| Sep 30, 2024 | 279,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Jun 30, 2024 | 134,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Mar 31, 2024 | 88,000.00 |
| Dec 31, 2023 | 174,164.00 |
| Dec 31, 2023 | 174,164.00 |
| Sep 30, 2023 | 171,283.00 |
| Sep 30, 2023 | 171,283.00 |
| Jun 30, 2023 | 168,157.00 |
| Jun 30, 2023 | 168,157.00 |
| Mar 31, 2023 | 110,396.00 |
| Mar 31, 2023 | 110,396.00 |
| Dec 31, 2022 | -364,546.00 |
| Dec 31, 2022 | -364,546.00 |
| Sep 30, 2022 | 91,875.00 |
| Sep 30, 2022 | 91,875.00 |
| Jun 30, 2022 | -91,875.00 |
| Jun 30, 2022 | -91,875.00 |